Background: Orbital atherectomy (OA) is a known alternative to other atherectomy
| MATERIALS AND METHODS

| Atherectomy device description
The Diamondback 360 coronary OA system (Cardiovascular Systems, Inc.
[CSI], St Paul, MN) was utilized in all cases analyzed. As previously reviewed, the mechanism of this device has been shown to be useful in the treatment of severely calcified, noncompliant coronary lesions prior to appropriate percutaneous transluminal coronary angioplasty and adequate stent deployment. 11 
| Study population
In this single center study, an IRB approved (IRB00094268) retrospec- 
| Primary safety and efficacy endpoint
Clinical documentation was abstracted and analyzed to determine the coronary revascularization success rate, procedural acute angiographic complication rates, and 30-day and 6.5-month median follow-up major adverse cardiac and cerebrovascular event rates (MACCE; defined as myocardial infarction requiring cardiac catheterization or intervention, stroke, target vessel revascularization, and death).
3 | RESULTS
| Baseline subject demographics
Forty subjects met all of the inclusion criteria for this retrospective analysis. The baseline subject demographics are shown in Cr > 2.5 mg/dL, of which five cases (12.5% of the total number of patients) were already on hemodialysis. This complex cohort also exhibited left ventricular systolic dysfunction-three patients had a left ventricular ejection fraction ≤25%. Lastly, the most common indication for percutaneous coronary intervention (PCI) was unstable angina followed by elective and myocardial infarction.
| Index lesion/vessel characteristics and procedural outcomes
As shown in Table 2 , trans-radial was the most common access site. 
| Angiographic complication rates and MACCE outcomes
The angiographic and MACCE outcomes are shown in Table 3 . Briefly, there was no evidence of in-stent thrombosis or significant coronary spasm in any of the cases. However, minor rates of coronary perforation (N = 1, 2.5%) and no-reflow (N = 1, 2.5%) occurred. None of the subjects experienced MACCE at index (in-hospital). The 30-day MACCE rate was 5%, and the two events were death (both cases were high risk with Impella assistance: one had coronary perforation which was successfully sealed and later had probable stent thrombosis due to suspected DAPT interruption, and the other died of multi-organ failure death (due to septic shock) and one target vessel revascularization occurred post 30 days.
| DISCUSSION
This single-center retrospective analysis of a Veterans Affairs cohort with severe coronary artery calcification revealed high efficacy and safety rates despite the complex disease state noted in these patients.
In addition, the high utilization rate of IVUS and Chocolate focal force angioplasty in combination with OA resulted in a large MSA.
The optimal results presented here are likely due to the unique mechanism of action of OA and Chocolate balloon angioplasty. As previously reviewed, OA has an orbital and differential sanding mechanism that reduces plaque burden, creating vessel compliance while minimizing damage to the medial layer of the vessel. [9] [10] [11] The
Chocolate balloon consists of a mounted nitinol constraining structure specifically designed for uniform, controlled inflation and rapid deflation, resulting in atraumatic dilatation without the need for cutting or scoring. Because of its novel design, it can enable focused force angioplasty from its "pillows" while allowing plaque channeling through its "grooves."
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In addition to the OA intraluminal plaque modification ability, it is also known that the OA crown creates pulsatile forces that result in fissures of the medial calcification. 13 Unlike intimal calcification, medial calcification results from elastin fiber mineralization and increased production of osteochondrogenic proteins, something typically seen in diabetes mellitus and CKD. 10 Thus, we hypothesize that there may be pulsatile forces that indirectly impact deeper calcification in the coronary vessel wall, similar to what has been shown with the peripheral OA device. 13 These medial fissures may be further expanded by the pillows of the Chocolate balloon resulting in one mechanism to account for the numerically larger average MSA (mm 2 ) seen in this study (mean ± SD 8. Chocolate balloon. 12 In addition, these results have important implications as it has previously been shown that greater post-intervention MSA is a predictor of better outcomes and patency. [14] [15] [16] Lastly, the angiographic complication and MACCE outcome rates seen in this VA retrospective analysis are similar to past OA clinical studies (ORBIT I, ORBIT II, and other multicenter studies), which have been extensively reviewed by others and compared with other atherectomy devices. [8] [9] [10] [11] In particular, patients with known CKD (including those on hemodialysis; excluded from ORBIT I), who are at higher risk for development of calcified lesions, as well as those with severe heart failure (left ventricular ejection fraction <25%; excluded from ORBIT I and II), were included in this analysis. Thus, the evidence presented here is crucial in providing a signal that OA may benefit complex patients, especially those at higher risk for development of severely calcified lesions and subsequent MACCE.
| Study limitations
This was a small, non-randomized, retrospective study with minimum Abbreviations: MACCE, major adverse cardiac and cerebrovascular events; MI, myocardial infarction; TVR, target vessel revascularization.
